Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Filoviridae Infections”

108 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 108 results

Large-scale testing (Phase 3)Looking for participantsNCT06126822
What this trial is testing

Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination with the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRC

Who this might be right for
Ebola Virus Disease
Institute of Tropical Medicine, Belgium 624
Early research (Phase 1)Study completedNCT02891980
What this trial is testing

A Safety Trial to Test MVA-BN(R)-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers

Who this might be right for
Ebola DiseaseMarburg Disease
National Institute of Allergy and Infectious Diseases (NIAID) 65
Early research (Phase 1)UnknownNCT04717830
What this trial is testing

An Open Study of the Safety and Pharmacokinetics of a Drug for the Emergency Prevention of Ebola Virus Disease

Who this might be right for
Ebola Virus Disease
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation 25
Testing effectiveness (Phase 2)Study completedNCT02598388
What this trial is testing

Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo

Who this might be right for
Hemorrhagic Fever, Ebola
Janssen Vaccines & Prevention B.V. 578
Not applicableStudy completedNCT06811129
What this trial is testing

Long-Term Neurologic and Neurocognitive Sequelae Following Pediatric Ebola Virus in Liberia

Who this might be right for
EbolaPost-Acute Ebola Syndrome
National Institute of Neurological Disorders and Stroke (NINDS) 328
Large-scale testing (Phase 3)Study completedNCT04228783
What this trial is testing

2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants

Who this might be right for
Ebola
Janssen Vaccines & Prevention B.V. 974
Testing effectiveness (Phase 2)Active Not RecruitingNCT06620003
What this trial is testing

A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults

Who this might be right for
Marburg Virus Disease
Albert B. Sabin Vaccine Institute 200
Early research (Phase 1)Study completedNCT02368119
What this trial is testing

Ebola CVD-Mali #2000 (Bivalent) VRC-EBOAdc069-00-vp (cAd3-EBO)

Who this might be right for
Ebola Virus DiseaseHemorrhagic Fever
University of Maryland, Baltimore 60
Not applicableUnknownNCT02333578
What this trial is testing

Clinical Trial to Evaluate the Efficacy and Safety of Convalescent Plasma for Ebola Treatment

Who this might be right for
Ebola Virus Disease
Clinical Research Management, Inc. 70
Early research (Phase 1)Study completedNCT00997607
What this trial is testing

Evaluating an Ebola and a Marburg Vaccine in Uganda

Who this might be right for
Ebola Virus DiseaseMarburg Virus Disease
National Institute of Allergy and Infectious Diseases (NIAID) 108
Large-scale testing (Phase 3)WithdrawnNCT05959421
What this trial is testing

Immunity Induced by VSV-EBOV and Assessment of a Booster Dose in Individuals at Potential Occupational Risk for Exposure

Who this might be right for
Ebola Vaccine
Universitätsklinikum Hamburg-Eppendorf
Early research (Phase 1)Study completedNCT04906629
What this trial is testing

INO-4201 as Booster in Healthy VSV-ZEBOV Vaccinees

Who this might be right for
Ebola Virus Disease
University of Geneva, Switzerland 46
Early research (Phase 1)Study completedNCT02464670
What this trial is testing

Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers

Who this might be right for
Ebola Vaccine
Inovio Pharmaceuticals 240
Testing effectiveness (Phase 2)Study completedNCT03333538
What this trial is testing

Randomized Placebo-controlled Study of Safety and Immunogenicity of GamEvac-Lyo

Who this might be right for
Healthy Volunteers
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation 220
Large-scale testing (Phase 3)WithdrawnNCT02307591
What this trial is testing

Clinical Study to Assess Efficacy and Safety of Amiodarone in Treating Patients With Ebola. Virus Disease (EVD) in Sierra Leone. EASE (EMERGENCY Amiodarone Study Against Ebola)

Who this might be right for
Ebola Virus Disease
Emergency NGO Onlus
Early research (Phase 1)Study completedNCT00646152
What this trial is testing

Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study

Who this might be right for
InfluenzaSevere Acute Respiratory Distress SyndromeSmallpox+2 more
National Institute of Allergy and Infectious Diseases (NIAID) 57
Large-scale testing (Phase 3)Study completedNCT03719586
What this trial is testing

Investigational Therapeutics for the Treatment of People With Ebola Virus Disease

Who this might be right for
Ebola Virus
National Institute of Allergy and Infectious Diseases (NIAID) 681
Post-approval studies (Phase 4)Active Not RecruitingNCT05992480
What this trial is testing

REVIVE (Response to the Ebola Virus Vaccine)

Who this might be right for
Ebola Virus Disease
Tulane University 40
Testing effectiveness (Phase 2)Study completedNCT02329054
What this trial is testing

Efficacy of Favipiravir Against Ebola (JIKI)

Who this might be right for
Ebola Virus Disease
Institut National de la Santé Et de la Recherche Médicale, France 126
Not applicableAvailableNCT05067166
What this trial is testing

Open-Label Expanded Access for Ebola-Infected Patients to Receive Human MAb Ansuvimab As Therapeutic or for HR PEP

Who this might be right for
Ebola Virus Disease
Ridgeback Biotherapeutics, LP
Load More Results